8x8 To Report First Quarter Fiscal 2015 Earnings On July 23, 2014

8x8, Inc. (NASDAQ:EGHT), a provider of cloud-based unified communications, contact center and collaboration solutions, today announced it will report its first quarter fiscal 2015 results for the period ended June 30, 2014 after market close on Wednesday, July 23, 2014. Following the announcement, a conference call hosted by 8x8 Chief Executive Officer Vik Verma and Chief Financial Officer Dan Weirich is scheduled to begin at 4:30 pm ET.

Details of the conference call are as follows:
Date:   July 23, 2014
Time: 4:30 pm ET
Dial In: (877) 843-0417, domestic
(408) 427-3791, international
Replay: (855) 859-2056, domestic (Conference ID #68270346)
(404) 537-3406, international (Conference ID #68270346)
Webcast:

http://investors.8x8.com
 

Participants should plan to dial in or log on ten minutes prior to the start time. A telephonic replay of the call will be available until midnight July 29, 2014. The webcast will be archived on 8x8’s website for a period of one year. For additional information, visit http://investors.8x8.com.

About 8x8, Inc.

8x8, Inc. (NASDAQ:EGHT) is the trusted provider of secure and reliable cloud-based unified communications and virtual contact center solutions to more than 37,000 small, midsize and distributed enterprise organizations operating in over 40 countries across six continents. 8x8's out-of-the-box cloud solutions replace traditional on-premise PBX hardware and software-based systems with a flexible and scalable Software as a Service (SaaS) alternative, encompassing cloud business phone service, contact center solutions, and web conferencing. For additional information, visit  www.8x8.com, or www.8x8.com/UK or connect with 8x8 on  Google+FacebookLinkedIn and  Twitter.

If you liked this article you might like

My Market Scans are Unimpressive

8x8 (EGHT) Stock Rises on Q1 Earnings Beat

8x8 (EGHT): Today's Weak On High Volume Stock

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan

'Mad Money' Lightning Round: Buy, Buy, Buy Seres Therapeutics